Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trappsol Cyclo in Early Alzheimer's Disease
NCT05607615Phase 2Unknown
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Trappsol Cyclo in Alzheimer's disease (AD), sponsored by Cyclo Therapeutics, Inc.. Status: unknown.
02
Drugs
Trappsol Cyclo
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05607615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607615.